Wissen Research analyses that the global amyotrophic lateral sclerosis market is estimated at USD 700 Million in 2024 and is projected to reach USD 993 Million by 2030, expected to grow at a CAGR of 6% during the forecast period, 2025-2030.
Key driving factors of amyotrophic lateral sclerosis market include rising incidence of ALS, particularly among the aging population, Development and approval of new drugs like Riluzole, Edaravone, and RELYVRIO are expanding treatment choices and improving patient outcomes, Investments in research by governments and collaborations between pharmaceutical companies and research institutions, among others
Challenges in the amyotrophic lateral sclerosis domain include high treatment costs, limited treatment options and regulatory barriers, among others.
Medication segment in treatment type have held the most significant share in the market since 2023, with North America dominating the regional market share.
Key players functioning in amyotrophic lateral sclerosis sector are Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., F. Hoffman-La Roche Ltd., Biogen Inc., Corestem, Biohaven Pharmaceutical, Sun Pharmaceutical Industries Ltd.
Further, the US with USD 240 Million market in 2024, holds majority share in the global amyotrophic lateral sclerosis market and is likely to remain the leading region growing a CAGR of 6% within this market, during the forecast period.
LUCRATIVE OPPORTUNITIES IN THE AMYOTROPHIC LATERAL SCLEROSIS MARKET
Global amyotrophic lateral sclerosis market is anticipated to reach USD 993 Million by 2030 from USD 700 Million in 2024, growing at an annualized rate of 6% during the period, 2025-2030 | Emerging economies such as India, China, Brazil, South Africa, and Turkey present significant growth opportunities for the Amyotrophic Lateral Sclerosis (ALS) market due to increasing prevalence rates and rising awareness of neurodegenerative diseases. While ALS remains relatively rare, the projected 69% increase in global cases by 2040, particularly in developing nations, highlights the growing demand for improved healthcare infrastructure and early diagnostic tools. Countries like China and India are witnessing heightened investments in healthcare, alongside government initiatives and non-profit campaigns promoting awareness and early detection. Additionally, expanding research and development efforts are driving innovative treatment approaches tailored to regional needs, including gene therapies and stem cell-based interventions | ASIA-PACIFIC Rising awareness, increasing healthcare investments, and a growing prevalence of neurodegenerative diseases in emerging markets like Southeast Asia and Latin America are expected to provide lucrative opportunities for Amyotrophic Lateral Sclerosis (ALS) market players |
Amyotrophic Lateral Sclerosis (ALS) treatment landscape has progressed with the approval of therapies such as riluzole and edaravone, which slow disease progression and improve functional outcomes. Relyvrio, a combination of sodium phenylbutyrate and taurursodiol, has emerged as a promising option for managing ALS symptoms. Experimental approaches like gene therapy, cellular therapy, and neuroprotective agents are being explored to address motor neuron degeneration and extend survival. Additionally, clinical trials for drugs like MN-166 (ibudilast) and masitinib are advancing, offering hope for innovative treatments targeting inflammation and neurodegeneration in ALS. | Emerging markets in Southeast Asia and Latin America are driving growth in the Amyotrophic Lateral Sclerosis (ALS) sector due to increasing healthcare investments and improved access to treatment options. In Southeast Asia, rising incomes and government-backed initiatives are boosting demand for advanced therapies, including stem cell treatments and neuroprotective agents. Similarly, Latin America is witnessing enhanced healthcare infrastructure and collaborations with global pharmaceutical companies, creating opportunities for innovative and cost-effective solutions to address the unmet needs of ALS patients. |
Amyotrophic Lateral Sclerosis (ALS) treatment landscape has progressed with the approval of therapies such as riluzole and edaravone, which slow disease progression and improve functional outcomes. Relyvrio, a combination of sodium phenylbutyrate and taurursodiol, has emerged as a promising option for managing ALS symptoms. Experimental approaches like gene therapy, cellular therapy, and neuroprotective agents are being explored to address motor neuron degeneration and extend survival. Additionally, clinical trials for drugs like MN-166 (ibudilast) and masitinib are advancing, offering hope for innovative treatments targeting inflammation and neurodegeneration in ALS. | Emerging markets in Southeast Asia and Latin America are driving growth in the Amyotrophic Lateral Sclerosis (ALS) sector due to increasing healthcare investments and improved access to treatment options. In Southeast Asia, rising incomes and government-backed initiatives are boosting demand for advanced therapies, including stem cell treatments and neuroprotective agents. Similarly, Latin America is witnessing enhanced healthcare infrastructure and collaborations with global pharmaceutical companies, creating opportunities for innovative and cost-effective solutions to address the unmet needs of ALS patients. |
Strategic Activities Within The Amyotrophic Lateral Sclerosis Market
Drivers: Rising prevalence of amyotrophic lateral sclerosis globally
The rising prevalence of Amyotrophic Lateral Sclerosis (ALS) is a significant driver of the market, fueled by demographic shifts such as the aging global population. Sporadic ALS, which accounts for 90%-95% of cases, is particularly prevalent among individuals aged 60 and older, with projections indicating substantial growth in cases by 2030, especially in developed regions like the United States and developing nations such as China and Iran. For instance, the U.S. is expected to see a 25% increase in ALS cases among individuals aged 66 years and older between 2022 and 2030. This trend underscores the growing demand for effective treatment options, including FDA-approved drugs like Riluzole and Edaravone, as well as emerging therapies such as stem cell treatments. The increasing prevalence not only drives innovation but also highlights the need for enhanced healthcare infrastructure to manage the disease’s socioeconomic burden effectively
Opportunities: Development of newer Novel Therapies
The development of novel therapies is reshaping the ALS market, with gene therapies and stem cell treatments leading innovation. Antisense oligonucleotides (ASOs) like Biogen’s Qalsody (tofersen), approved for SOD1-ALS, demonstrate the potential of gene-silencing to reduce toxic protein buildup14. Similarly, Ionis Pharmaceuticals’ ulfernesen targets FUS mutations, while QurAlis’ ASO aims to restore STMN2 expression—a protein critical for neural repair in sporadic ALS cases4. Stem cell therapies, such as mesenchymal stem cell (MSC) transplants, show promise in delaying disease progression by modulating neuroinflammation and preserving motor neurons, as evidenced by preclinical studies and trials by institutions like DVC Stem26. Advances in CRISPR-based gene editing and AAV-mediated delivery systems further expand therapeutic possibilities for both familial and sporadic ALS15. These breakthroughs, coupled with initiatives like the HEALEY ALS Platform Trial accelerating drug evaluation, underscore a transformative shift toward disease-modifying treatments with broader patient applicability
Challenges: High treatment costs and limited insurance coverage for specialized ALS therapies
The high costs associated with ALS treatments significantly limit accessibility, particularly in low-income regions, creating a major challenge for the market. Annual expenses for ALS patients can reach up to $143,000, including direct costs such as medications, medical equipment, and hospital stays, as well as indirect costs like lost wages and home care. For example, FDA-approved drugs like Riluzole cost up to $12,000 per year, while Edaravone can exceed $145,000 annually. Advanced interventions like tracheostomy and invasive ventilation add further financial strain, costing between $150,000 and $330,000 per year. Additionally, the need for specialized equipment such as power wheelchairs or patient lifts can total tens of thousands of dollars.
Stem cell therapy to witness the most growth in the amyotrophic lateral sclerosis market in forecast period (2025-2030)
In 2024, the medication segment captured 60% of the market share. This dominance is attributed to medications’ role in targeting ALS’s underlying mechanisms, thereby extending survival and enhancing quality of life. The increasing awareness of ALS and advancements in drug development are key factors driving the demand for effective pharmacological treatments.
Meanwhile, stem cell therapy is anticipated to experience the most rapid growth, with a projected CAGR of 7% over the forecast period (2025-2030). The market is witnessing heightened interest in stem cell therapy due to its potential to address ALS through cell replacement, neuroprotection, and modulation of inflammation.
Sporadic ALS accounted for the largest share in amyotrophic lateral sclerosis market by disease type in 2024
Sporadic ALS captured the largest revenue share of 85% in 2024, primarily driven by its widespread prevalence, accounting for 90%-95% of all ALS cases. The increasing incidence among the aging population, coupled with rising awareness of the disease, has significantly boosted demand for effective treatments. Unlike familial ALS, sporadic ALS lacks a clear genetic link, presenting unique challenges for research and drug development. These complexities have spurred innovation in therapeutic solutions, with FDA-approved medications such as Riluzole and Edaravone playing pivotal roles in managing disease progression and improving patient outcomes.
Familial ALS, though less common, is expected to grow at the fastest CAGR of 6.5% during the forecast period due to its hereditary nature. With a 50% chance of transmission to offspring, familial ALS has driven advancements in genetic research and targeted therapies, creating opportunities for specialized treatment approaches.
Significant market share held by hospital pharmacies was observed in 2024
Hospital pharmacies dominated the amyotrophic lateral sclerosis (ALS) treatment market in 2024, accounting for a revenue share of 55%. This leadership is driven by the frequent hospital stays and visits required by ALS patients for treatment and disease management. Hospital pharmacies are preferred due to their ability to provide easy access to a comprehensive range of ALS medications, including FDA-approved drugs like Riluzole and Edaravone, ensuring adequate stock and specialized care
North America held the largest market share in amyotrophic lateral sclerosis in the forecast period (2025-2030)
Amyotrophic Lateral Sclerosis (ALS) market research included a comprehensive analysis of five key regions:
All regions were evaluated based on these following factors- healthcare infrastructure, regulatory landscape, technological adoption, and market dynamics.
The research observed that North America held the largest share in the amyotrophic lateral sclerosis (ALS) treatment market domain during the forecast period, primarily due to its advanced healthcare systems, high adoption rates, and the presence of major market players driving innovation in this sector.
Major players operating in amyotrophic lateral sclerosis market are:
BRAND ANALYSIS: AMYOTROPHIC LATERAL SCLEROSIS MARKET
Sources: Secondary Research
PRIMARY INSIGHTS
PRIMARY INSIGHTS FROM KEY OPINION LEADERS
Sources: Primary Research and Wissen Research Analysis.
Note: Above mention is non-exhaustive samples of the primary insights.
Particulars | Details |
Report | Amyotrophic Lateral Sclerosis Market |
Forecast Period | 2025-2030 |
Base Year | 2024 |
Format | |
Estimated Market Size (2024) | USD 700 Million |
CAGR (2025-2030) | 6% |
Number of Pages | 170 |
Number of Tables | 161 |
Number of Figures | 33 |
Key Segments | Amyotrophic Lateral Sclerosis Market Treatment Outlook (Medication, Stem Cell Therapy, Others)
Amyotrophic Lateral Sclerosis Market Disease Outlook (Sporadic ALS, Familial ALS) Amyotrophic Lateral Sclerosis Market Drugs Outlook (Riluzole, Edaravon, Others) Amyotrophic Lateral Sclerosis Market Distribution Channels Outlook (Hospitals Pharmacies, Retail Pharmacies and Drug Stores, Online Pharmacies) |
Regions Covered |
|
Key Players Covered (Majority Share Holders) | Mitsubishi Tanabe Pharma Corporation (Japan), Otsuka Pharmaceutical Co., Ltd. (Japan), F. Hoffman-La Roche Ltd. (Switzerland), Biogen Inc. (US), CORESTEMCHEMON Inc. (South Korea), Biohaven Pharmaceutical (US), Sun Pharmaceutical Industries Ltd. (India), Ionis Pharmaceuticals, Inc. (US), Amylyx Pharmaceuticals, Inc. (US), Orion Corporation (Finland), AB Science (France), Alkem Laboratories Ltd (India), Viatris Inc. (US) |
In order to give the most precise estimations and forecasts, Wissen Research uses an extensive and iterative research approach that is focused on reducing deviation. The company blends top-down and bottom-up methodologies for market segmentation and quantitative estimation. In addition, data triangulation, which examines the market from three separate angles, is a recurrent topic present in all of our research studies. Important components of the approach used for all of our studies include the following:
Preliminary data mining
On a wide scale, unprocessed market data is collected. Continuous data filtering makes sure that only verified and authenticated sources are taken into account. Additionally, data is extracted from a wide range of reports in our repository and from a number of reputable premium databases. We gather information from raw material suppliers, distributors, and purchasers to help with this since understanding the entire value chain is crucial for a thorough understanding of the market.
Surveys, technical symposia, and trade magazines are used to gather information on technical concerns and trends. Technical information focusing on white space and freedom of movement is also obtained from an intellectual property standpoint. Additionally, information on the industry’s drivers, constraints, and pricing patterns is obtained. As a result, a variety of original data are included in the material that is then cross-validated and certified with published sources.
Statistical model
We use simulation models to generate our market projections and estimates. Every study receives a special model that is tailored to it. Data for market dynamics, the technology environment, application development, and pricing patterns are gathered and supplied into the model all at once for analysis. The relative relevance of these factors is investigated, and their impact on the forecast period is assessed, using correlation, regression, and time series analysis. The process of market forecasting combines technological analysis with economic strategies, practical business acumen, and subject expertise.
Econometric models are frequently used for short-term forecasting, but technology market models are typically employed for long-term forecasting. These are based on a confluence of the business environment, regulatory environment, economic projection, and technical landscape. In order to develop global estimates, it is preferable to estimate markets from the bottom up by integrating data from key regional markets. This is required to ensure accuracy and a complete comprehension of the subject. Among the variables taken into account for forecasting are:
Regulations and anticipated developments
We give these criteria weights and use weighted average analysis to assess their market influence in order to calculate the anticipated market growth rate.
Primary research | Secondary research |
· Manufacturers · Technology distributors and wholesalers · End-user surveys · Consumer surveys | · Company reports and publications · Government publications · Independent investigations · Economic and demographic data · Online searches · Research reviews · Reference customers |
1. Introduction
1.1 Key Objectives
1.2 Definitions
1.2.1 In Scope
1.2.2 Out of Scope
1.3 Scope of The Report
1.4 Scope Related Limitations
1.5 Key Stakeholders
2. Research Methodology
2.1 Research Approach
2.2 Research Methodology / Design
2.3 Market Sizing Approach
2.3.1 Secondary Research
2.3.2 Primary Research
3. Executive Summary & Premium Content
3.1 Global Market Outlook
3.2 Key Market Findings
4. Market Overview
4.1 Market Dynamics
4.1.1 Drivers/Opportunities
4.1.2 Restraints/Challenges
4.2 End User Perception
4.3 Need Gap
4.4 Supply Chain / Value Chain Analysis
4.5 Industry Trends
4.6 Regulatory Landscape
4.7 Porter’s Five Forces Analysis
4.8 Pricing Analysis
4.9 Reimbursement Scenario
5. Patent Analysis
5.1 Top Assignees in Amyotrophic Lateral Sclerosis Market
5.2 Geography Focus of Top Assignees
5.3 Legal Status of Amyotrophic Lateral Sclerosis Patents
5.4 Assignee Segmentation
5.5 Network Analysis of Top Collaborating Entities in Amyotrophic Lateral Sclerosis Patent Applications
5.6 Technology Evolution in Amyotrophic Lateral Sclerosis
5.7 Key Patents in Amyotrophic Lateral Sclerosis
5.8 Patent Trends and Innovations
5.9 Key Players and Patent Portfolio Analysis
6. Clinical Trial Analysis
6.1 Overview of Amyotrophic Lateral Sclerosis Clinical Trials
6.2 Analysis by Trial Registration Year
6.3 Analysis by Phase of Development
6.4 Analysis by Number of Patients Enrolled
6.5 Analysis by Status of Trial
6.6 Analysis by Study Design
6.7 Analysis by Intervention Type
6.8 Analysis by Geography
6.9 Analysis by Key Sponsors/Collaborators
7. Amyotrophic Lateral Sclerosis Market, by Disease Type (2024-2030, USD Million)
7.1 Sporadic ALS
7.2 Familial ALS
8. Amyotrophic Lateral Sclerosis Market, by Treatment Type (2024-2030, USD Million)
8.1 Medication
8.2 Stem Cell Therapy
8.3 Others
9. Amyotrophic Lateral Sclerosis Market, by Drugs (2024-2030, USD Million)
9.1 Riluzole
9.2 Edaravone
9.3 Others
10. Amyotrophic Lateral Sclerosis Market, by Distribution Channels (2024-2030, USD Million)
10.1 Hospitals Pharmacies
10.2 Retail Pharmacies and Drug Stores
10.3 Online Pharmacies
11. Amyotrophic Lateral Sclerosis Market, by Region (2024-2030, USD Million)
11.1 North America
11.1.1 US
11.1.2 Canada
11.2 Europe
11.2.1 UK
11.2.2 France
11.2.3 Germany
11.2.4 Italy
11.2.5 Spain
11.2.6 Rest of Europe
11.3 Asia Pacific
11.3.1 China
11.3.2 India
11.3.3 Japan
11.3.4 South Korea
11.3.5 Australia and New Zealand
11.3.6 Rest of Asia Pacific
11.4 Middle East and Africa
11.5 Latin America
12. Competitive Analysis
12.1 Key Player’s Footprint Analysis
12.2 Market Share Analysis
12.3 Key Brand Analysis
12.4 Regional Snapshot of Key Players
12.5 R&D Expenditure of Key Players
13. Company Profiles2
13.1 Mitsubishi Tanabe Pharma Corporation
13.1.1 Business Overview
13.1.2 Product Portfolio
13.1.3 Financial Snapshot3
13.1.4 Recent Developments
13.1.5 SWOT Analysis
13.2 Otsuka Pharmaceutical Co., Ltd.
13.3 Hoffman-La Roche Ltd.
13.4 Biogen Inc.
13.5 Corestem
13.6 Biohaven Pharmaceutical
13.7 Sun Pharmaceutical Industries Ltd.
13.8 Ionis Pharmaceuticals, Inc.
13.9 Amylyx Pharmaceuticals, Inc.
13.10 Orion Corporation
13.11 AB Science
13.12 Alkem Laboratories Ltd
13.13 Viatris Inc.
13.14 Others Key Players
14. Appendix
14.1 Industry speak
14.2 Questionnaire
14.3 Available custom work
14.4 Adjacent studies
14.5 Authors
15. References
Key Notes:
Note 1 – Contents in the ToC / market segments are tentative and might change as the research proceeds.
Note 2 – List of companies is not exhaustive and might change during the course of study.
Note 3 – Details on key financials might not be captured in case of unlisted companies.
Note 4 – SWOT analysis will be provided for top 3-5 companies.
The global market for amyotrophic lateral sclerosis was valued at approximately USD 700 Million in 2024, and is projected to increase to USD 742 Million in 2025.
The global amyotrophic lateral sclerosis market is anticipated to grow at an annual growth rate of 6% from 2025 to 2030 to reach USD 993 Million, by 2030.
The major distribution channels in the amyotrophic lateral sclerosis market include Hospitals Pharmacies, Retail Pharmacies and Drug Stores, Online Pharmacies. Hospital Pharmacies remained the significant holder of distribution channels market share due to growing significance of disease and the rise in number of indoor patients.
Leading players within the amyotrophic lateral sclerosis market are Mitsubishi Tanabe Pharma Corporation (Japan), Otsuka Pharmaceutical Co., Ltd. (Japan), F. Hoffman-La Roche Ltd. (Switzerland), Biogen Inc. (US), CORESTEMCHEMON Inc. (South Korea)
The market is highly consolidated at top, comprising 3-5 key players with them holding almost 80% of the market, while it remains lightly fragmented at the lower levels, with numerous small and mid-sized companies operating at regional and national level.
